INVIMA page-one rankings for “approval” still convert poorly when the article is about a clinical trial. This checklist is the other file: registro sanitario / market authorization for a medical device you intend to import and sell in Colombia — holder, importer, Spanish dossier, UDI — not a first-in-human CEI/INVIMA trial pack.
bioaccess® is U.S.-anchored in Miami and supports U.S. MedTech sponsors on both clinical execution and market access across 19 Latin American and Caribbean markets. The ranges below are planning ranges from that work in 2026. They are not INVIMA guarantees, and they are not a promise that a new decree will freeze today’s clocks.
What INVIMA registration is
INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) is Colombia’s Level 4 PAHO/WHO authority and an IMDRF participant. Device market access still sits primarily on Decree 4725 of 2005 (devices) and Decree 3770 of 2004 (IVDs), with Resolution 1405 of 2022 driving UDI-DI and semantic reporting. A modernization decree to replace 4725 has been in motion through 2026 (IMDRF-aligned safety/performance language, ISO 13485 as the explicit GMP reference, personalized-device language). Until that decree is in force, plan against 4725 and treat “the new decree will save us a quarter” as speculation.
Two structural facts U.S. RA teams get wrong. First, the manufacturer remains the owner of the sanitary registration even without a Colombian office — unlike Mexico, where the local holder typically owns the number. Second, you still cannot operate the file yourself: you appoint a Colombia-domiciled Legal Representative (representante legal) and you identify an importer that already holds a valid CCAA (Certificado de Capacidad de Almacenamiento y Acondicionamiento).
Classification: uncontrolled vs controlled
Colombia’s four-class scheme (I, IIa, IIb, III) tracks EU-style risk rules more closely than FDA’s three classes. Borderline products should be classified in Colombia, not copied from a 510(k) letter.
- Uncontrolled (Class I and IIa). A complete application can receive immediate certificate issuance. You may import while INVIMA reviews the technical file after the number exists. That is not “no review.” Ignore a post-approval information request and the registration can be wound back.
- Controlled (Class IIb and III). Full pre-market technical review. Practitioner calendars of 6–8 months of INVIMA time are common; 8–12 months start-to-number is a safer sponsor calendar once translations and CFS lead time are included. Clinical and performance evidence are expected, not optional appendices.
Holder and importer checklist (do this before tramites.invima.gov.co)
- Legal Representative appointment. Mandatory under 4725 for foreign manufacturers. The RL submits, receives oficio, and owns the response clock. Switching RL after approval is a formal modification, not a vendor swap.
- Importer with a live CCAA. Storage and conditioning capacity is a licensed activity. Name the importer in the application. If your commercial distributor’s CCAA lapses, your import lane lapses with it.
- Decide whether RL and importer are the same entity. Combining them is operationally simple and strategically sticky. Splitting them costs more coordination and protects you when the commercial relationship changes.
- Keep manufacturer ownership visible in the power of attorney and in how labeling shows the legal manufacturer vs. the importer.
Dossier checklist (Spanish, not “English plus a cover letter”)
Evidence INVIMA actually blocks on
- CFS or CFG from the country of origin or a recognized reference market (United States, Europe, Canada, Japan, Australia). This is the document that slips the calendar — FDA export certificates and notified-body paperwork have their own queues.
- ISO 13485 (or equivalent QMS) covering the legal manufacturer and the device scope you are registering.
- Technical file in Spanish: description, intended use, classification rationale, specifications, manufacturing overview.
- Risk management consistent with ISO 14971 thinking.
- Test reports expected for IIa and required in practice for IIb/III (bench, biocompatibility, electrical, software — whatever the device actually is).
- Clinical evidence for IIb/III: investigation reports, clinical evaluation, or a literature-based CER that can survive a reviewer who has seen EU MDR files.
- Spanish labeling and IFU, with space for the INVIMA registration number and the importer identity.
- RL authorization / power of attorney and the importer’s CCAA evidence.
UDI-DI and semantic reporting (2026 is not “upcoming”)
Resolution 1405/2022 is in force. Holders obtain UDI-DI codes from a recognized issuing agency (GS1, HIBCC, ICCBBA, and the other agencies INVIMA lists) and complete semantic reporting on INVIMA’s platform. The deferred deadline for many Class I / IIa / Category I IVD records ran through early February 2026. If you already have a Colombian number and you have not closed UDI-DI plus the semantic report, treat commercialization as at risk — INVIMA has been explicit that noncompliant records should not be sold against. New registrations should build UDI into the launch pack, not a “phase 2.”
Fees, validity, and the calendar
INVIMA government fees are published in Colombian pesos and change. Recent practitioner tables put device application tariffs roughly in the COP 3.9–4.4 million band by uncontrolled vs. controlled pathway (IVDs somewhat lower). That is the state tariff, not the project. Legal-representative retainers, certified translations, and controlled-pathway deficiency cycles are the real budget. There is no honest single “$5,500 all-in Colombia registration” number that survives contact with a Class III implant and a stale CFS.
Certificates are typically valid 10 years. File renewal on the order of three months before expiry. Technovigilance is continuous: serious incidents and field actions route through the RL into INVIMA’s program. Quarterly discipline beats a once-a-year “PMS cleanup.”
FAQ-style close
Is INVIMA registration the same as INVIMA clinical-trial authorization? No. Trial submissions, CEI/IRB, and import of investigational units are a different operating system. This checklist is for a device you will commercialize.
Does FDA or CE mark create automatic INVIMA approval? No formal equivalency pathway like Mexico’s abbreviated route. A U.S. or EU CFS/CFG is mandatory evidence, not a stamp that skips the file.
Who holds the number? The manufacturer owns the registration. The RL and the CCAA importer operate it. Write those contracts so a distributor change does not hold your sanitary registration hostage.
Where does this sit in a multi-country launch? Colombia is often the Andean first filing because of the uncontrolled path for I/IIa and a 10-year certificate. Sequence CFS procurement first. If you already have FDA-cleared or CE-marked devices and want a register-and-hold model across LATAM rather than a one-off INVIMA project, the structured offer is on bioaccess®’s market-access / LATAM Launch Subscription page.